Abstract
Overview
Introduction
Incidence of primary brain cancer across the seven major markets in 2007 is
estimated to be 47,000. Over half of these cases will be glioblastoma
multiforme, for which survival prospects are dismal. The median survival for
this group of patients is 1.2 years and only 27% of patients are alive after
two years. The level of unmet need is therefore high in this disease.
Scope
- Incidence, diagnosis and treatment of primary brain cancer, including
treatment regimens by stage and ongoing controversies
- Unmet needs, emerging trends and commercial incentives in primary brain
cancer
- Examination of pipeline activity and potential future opportunities for
drug developers
- Stakeholder opinions and interview transcripts based on qualitative
interviews with six opinion leaders from the US and Europe
Highlights
The standard set by drugs that have been approved for primary brain cancer is
low; therefore drugs only need to demonstrate relatively modest improvements
in survival to be adopted by physicians. A substantial opportunity also exists
for a second-line chemotherapy to enter the primary brain cancer market.
Several molecular markers have been associated with glioma. It is possible
that these markers could significantly affect treatment patterns, resulting in
a stratified glioma market. Targeted therapies could be reserved solely for
patients whose molecular profile indicates that they will benefit from such
drugs.
The potential of Phase III pipeline drugs is limited by factors such as low
efficacy and complicated delivery methods. Of the drugs in the Phase II
pipeline for glioma, targeted therapies show most potential. In particular,
angiogenesis inhibitors have considerable commercial potential because they
may reduce the co-morbidity edema.
Reasons to Purchase
- Identify the limitations of current therapy available to primary brain
cancer patients and the potential of future therapy
- Understand current epidemiological trends in primary brain cancer and
ongoing treatment controversies
- Assess the opportunities for innovative targeted therapies in primary
brain cancer, particularly in recurrent disease
View Cart
